Advancing First & Best-In-Class mRNA Vaccines & Therapies from Concept to Commercialisation with Targeted Delivery, Better Tolerability & Clinical Safety to Combat All Diseases

With GSK’s €1.4Bn investment into acquiring CureVac’s infectious disease pipeline, Moderna and BioNTech’s initiation of personalised cancer vaccine trials, and the emergence of novel mRNA applications in protein replacement therapy, gene editing and in vivo cell engineering, the mRNA industry is observing huge value R&D opportunities that will open the floodgates towards clinical and market approval in 2025.

The 4th mRNA-Based Therapeutics Summit Europe returned to Frankfurt, Germany as the industry’s premier forum dedicated to showcasing the hottest disease targets, never-before-seen pre-clinical and clinical data, and demonstrating key routes to commercial success for mRNA therapy and vaccine R&D pipelines.

Whether you’re entering the mRNA arena for the first time or a well-seasoned mRNA veteran, with two dedicated tracks of content spanning discovery through commercialisation, this forum equipped attendees with the know-how and connections to make rapid advances in your work with partnering and collaborative networking opportunities spread throughout.

Assembling 200+ mRNA enthusiasts from across Europe, Asia and the globe, this was the one-stop-shop to gain unparalleled overview of cutting-edge R&D innovations, whilst diving deep into end-to-end development strategy to revolutionise the next wave of mRNA medicines towards clinical reality.